Why the study?
Does ACEI/ARB discontinuation increase the risk of death and ESKD in predominantly male veterans with CKD Stages 3 and 4?
Does ACEI/ARB discontinuation increase the risk of death and ESKD in predominantly male veterans with CKD Stages 3 and 4?
Answers are grounded in this paper and cite their sources.
Discontinuation of ACEI/ARB therapy in patients with CKD Stages 3 and 4 is associated with higher risks of death and ESKD, though this may be confounded by underlying illness severity.
In a cohort of predominantly male veterans with CKD Stages 3 and 4, ACEI/ARB discontinuation was independently associated with an increased risk of subsequent death and ESKD. This may be due to the severity of illness factors that drive the decision to discontinue therapy. Further investigations to determine the causes of discontinuations and to provide an evidence base for discontinuation decisions are needed.
No takes yet. Share an insight, caveat, or question.
Walther et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: